移植后循环胺改善了HLA-DPB1不匹配的非相关捐赠者的生存率
Shannon R McCurdy1, Scott R Solomon2, Brian C Shaffer3
1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia.
Transplantation and cellular therapy
|October 3, 2025
概括
移植后循环胺 (PTCy) 是一种优越的移植对宿主疾病 (GVHD) 预防方法,与非相关的捐赠者造血细胞移植 (HCT) 中的甲铁和塔克罗利 (MTX/Tac) 相比. PTCy允许比较的生存结果,无论HLA-DPB1匹配状态如何.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 移植医学 移植医学
背景情况:
- HLA-DPB1不匹配在与无关的捐赠者造血细胞移植 (HCT) 中很常见,并且与传统预防的移植对宿主疾病 (GVHD) 风险增加有关.
- 之前的指导方针强调了HLA-DPB1对非相关捐赠者的匹配,但其与新型预防策略 (如移植后环胺 (PTCy) 的作用) 的作用仍未得到充分探索.
研究的目的:
- 评估GVHD预防策略 (PTCy与MTX/Tac) 与总生存率 (OS) 以及T细胞复制URD HCT中无GVHD,无复发生存率 (GRFS) 之间的关联.
- 确定HLA-DPB1匹配 (非允许不匹配,允许不匹配或匹配) 在使用不同GVHD预防方案时对结果的影响.
主要方法:
- 使用国际血液和骨髓移植研究中心 (CIBMTR) 数据库进行回顾性队列研究.
- 在2015-2020年期间,针对急性白血病或骨髓质疏松综合征进行首次高血压试验的成年患者的分析.
- 在不同HLA-DPB1匹配场景中,在接受基于PTCy或基于MTX/Tac的GVHD预防的患者之间比较结果 (OS,GRFS,与治疗相关的死亡率,复发).
主要成果:
- 与PTCy相比,HLA-DPB1与MTX/Tac预防的非容许性不匹配与较高的治疗相关死亡率,较低的复发率,较低的整体存活率和更糟糕的GRFS有关.
- 与MTX/Tac.相比,PTCy预防表明GRFS明显更好 (54%与1年后的40%相比)
- 在使用PTCy时,在HLA-DPB1非允许不匹配,允许不匹配或与HLA匹配的非相关捐赠者之间没有观察到结果的显著差异.
结论:
- 移植后的循环胺应该是HLA-DPB1不匹配的非相关的捐赠者HCT的首选GVHD预防方法.
- 在使用基于PTCy的GVHD预防时,HLA-DPB1不匹配不应成为避免与无关的捐赠者的理由,因为在HLA-DPB1匹配状态中,生存结果是可比的.
更多相关视频
相关概念视频
Tissue Transplantation
907
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
907
Bone Marrow Sampling and Transplants
881
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
881
Kidney Transplant II: Surgical Procedure
307
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
307
Kidney Transplant I: Introduction
340
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
340


